Researchers in Hyderabad say diabetes drug may work for Kovid-19

Researchers in Hyderabad say diabetes drug may work for Kovid-19

Hyderabad: A team of researchers from Hyderabad has found that the anti-diabetic drug Ertugliflozin can work against Covid-19.

Researchers from ReaGene Innovations Private Limited, a startup company incubated at ASPIRE-BioNEST, sponsored by the University of Hyderabad and the Department of Biotechnology (DBT), and INDRAS Private Limited have a rationale for the anti-diabetic drug Ertugliflozin as a buyback drug. In-vitro and in-silico studies, respectively, may provide a therapeutic solution for Covid-19 infection. Their findings indicate that this repurposed drug not only effectively binds to the receptor binding domain of the spike protein of Covid-19, but further blocks the binding. Human ACE2 (a receptor to which the Covid-19 virus binds itself) but also exhibits significant anti-inflammatory and antithrombotic properties in a 3D human vascular lung model, both of which are fundamental in Covid-19 infection.

This is the first result that offers a safe, ready-to-use, cost-effective solution for humans who are infected with COVID-19. Dr. Uday Saxena, CEO, Regine Innovations, co-founded with Dr. Subramaniam Vangala and Dr. Sridhar Voleti, MD, said, “It has immense potential for treating COVID-19 infection, and our research proves its effectiveness in test-tube assays. is.” Why Indras? Ertugliflozin is an FDA approved drug for type-2 diabetes, works as an SGLT-2 inhibitor by removing excessive glucose through urine.


you successfully cast your vote

INDRAS’s focus is on consulting, contracting and collaborative solutions for in-silico drug design, it has prioritized approximately 8000 FDA approved drugs in the top-10 from its computational studies, which have been identified as regimens for various in-vitro assays on cytokine storms. was further experimented by innovation. Antithrombotic properties, and reduction in inflammatory markers through various in vitro assays, according to an official statement from the University of Hyderabad.

The path to finding such a repurchased drug was critically planned and completed within a year of funding from IT giant Tech Mahindra. The Tech Mahindra team led by Dr. Ratnakar Palkodetti, Global Practice Head of Life Sciences and Mr. Nikhil Malhotra, Global Head of Makers Lab, in collaboration with the scientific partnership of INDRAS and Regine, brought this useful innovation to the humanity affected by COVID. Made extremely helpful. -19. The results of this research were recently published in a journal (BioRxIV) and a patent was filed in both India and the PCT. “We have found a molecule that can potentially attack the coronavirus. We have applied for a joint patent,” Malhotra said. The results obtained are highly encouraging, and further preclinical results in animal models and clinical results in humans have not yet been conducted to confirm this drug. to be officially designated as the therapeutic agent for COVID-19.

ASPIRE-BioNEST is a life sciences incubator jointly funded by BIRAC, a non-profit organization of the Department of Biotechnology, Government of India. India and the University of Hyderabad (UoH) have achieved their goals by providing plug-and-forth with a commitment to nurture start-ups such as Regine Innovations to nurture scaling technologies through entrepreneurship, located at the School of Life Sciences, University of Hyderabad. helped to obtain. play facility.


Leave a Reply

Your email address will not be published. Required fields are marked *